Sansure Biotech Inc (688289) — Cash Flow-to-Debt Ratio
Sansure Biotech Inc (688289) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥59.72 Million could theoretically repay 0% of its total liabilities (CN¥2.24 Billion) in one year. See 688289 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sansure Biotech Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Sansure Biotech Inc across 8 annual periods. Also explore Sansure Biotech Inc (688289) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sansure Biotech Inc (2017–2024)
Year-by-year debt coverage analysis for Sansure Biotech Inc. For market capitalisation and broader financial context, see Sansure Biotech Inc (688289) total market value.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.22x | CN¥274.45 Million | CN¥1.26 Billion | ▲ +99.0% |
| 2023 | 0.11x | CN¥112.82 Million | CN¥1.03 Billion | ▼ -92.9% |
| 2022 | 1.54x | CN¥2.56 Billion | CN¥1.66 Billion | ▼ -41.8% |
| 2021 | 2.65x | CN¥1.88 Billion | CN¥709.03 Million | ▼ -29.0% |
| 2020 | 3.73x | CN¥2.64 Billion | CN¥708.95 Million | ▲ +1313.7% |
| 2019 | 0.26x | CN¥22.41 Million | CN¥84.99 Million | ▲ +307.9% |
| 2018 | 0.06x | CN¥10.07 Million | CN¥155.76 Million | ▲ +119.6% |
| 2017 | -0.33x | CN¥-61.44 Million | CN¥186.62 Million | — |